Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort

Status:

WITHDRAWN

Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort

Lead Sponsor:

Germans Trias i Pujol Hospital

Conditions:

HIV Infections

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

This project wills to determine the incidence of osteoporosis in our population of HIV-infected patients and to assess the efficacy and security of ibandronate, whose efficacy in post-menopausal women...

Detailed Description

The lower bone mineral density that has been described in patients with HIV-infection has not meant an increase of long term complications. Nevertheless, it could involve an increase if the associated...

Eligibility Criteria

Inclusion

18 years old or elder.
Documented HIV-1 infection, with or without antiretroviral treatment.
Presence of WHO osteoporosis criteria, defined as t-score under -2.5 in lumbar, hip and/or trochanter. (DEXA in the last 6 months is needed)
Willing to follow the study protocol.
Informed Consent signature.

Exclusion

In women, pregnancy or breastfeeding.
Other possible causes of secondary osteoporosis.
Creatinin over 2.3mg/mL
Glomerular filter less than 50 mL/min (estimated through MDRD)
Alendronate treatment in the last 6 months.

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00662077

Last Update

March 13 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)